SMILR and peripheral arterial disease: SMILR expression increases in both the cytoplasm and nucleus of VSMCs during phenotypic switching, subsequently leading to its release into the extracellular space, which allows for the detection of SMILR in plasma, making it a potential biomarker for patients at risk of atherosclerosis-related PAD.